3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
3
Urologic Diseases
2
Urinary Bladder Diseases
2
Carcinoma, Transitional Cell
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
20
atezolizumab
9
Nivolumab
9
Gemcitabine
9
Docetaxel
5
avelumab
4
Mitomycin
4
Carboplatin
4
fludarabine
3
epacadostat
3
enfortumab vedotin
3
Cyclophosphamide
3
vofatamab
2
valrubicin
2
rucaparib
2
pemigatinib
2
durvalumab
2
cabozantinib
2
Standard of Care
2
Sirolimus
2
Radiation
2
Pemetrexed
2
Cisplatin
2
Bevacizumab
2
B701 protein, Human herpesvirus 6
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
trilaciclib
1
temsirolimus
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma, Transitional Cell
×
vofatamab
×
Clear all
NCT03123055
2020-03-18
FIERCE-22
Rainier Therapeutics
Phase 1/2
Terminated
28 enrolled
8 charts
NCT02401542
2020-03-09
FIERCE-21
Rainier Therapeutics
Phase 1/2
Terminated
71 enrolled
9 charts